Design of an automated enhanced- throughput platform for functional characterization of positive allosteric modulator-induced leftward shifts in apparent agonist potency in vitro

Journal of Laboratory Automation

Volumn 17, Issue 2, 2012, Pages 104-115

  Hendricson, Adam W ^a   Matchett, Michele ^a   Ferrante, Meredith ^a   Ferrante, Chris ^a   Hunnicutt, Ed ^a   Westphal, Ryan ^a   Kostich, Walt ^a   Huang, Yanling ^a   Masias, Nelly ^a   Hong, Debra ^a   Bertekap, Rob ^a   Burford, Neil ^a   Watson, John ^a   Alt, Andrew ^a   Myslik, Jim ^a   Zhang, Litao ^a   Knox, Ron ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Allosteric modulator; Automation; Functional assay; GPCR

Indexed keywords

AUTOMATION; PULSE AMPLITUDE MODULATION;

ALLOSTERIC MODULATION; ALLOSTERIC MODULATORS; AUTOMATION CONTROLS; FUNCTIONAL ASSAYS; FUNCTIONAL CHARACTERIZATION; GPCR; LABORATORY TECHNOLOGIES; POSITIVE ALLOSTERIC MODULATOR;

MODULATORS;

CHEMICAL COMPOUND; G PROTEIN COUPLED RECEPTOR; POSITIVE ALLOSTERIC MODULATOR; UNCLASSIFIED DRUG; ION CHANNEL;

ACCURACY; ALLOSTERISM; ANALYTICAL EQUIPMENT; ANALYTICAL PARAMETERS; ARTICLE; ASSAY; AUTOANALYSIS; AUTOMATED FUNCTIONAL AGONIST SHIFT ASSAY; CONCENTRATION RESPONSE; CONCENTRATION RESPONSE CURVE FUNCTIONAL ASSAY; CONTROLLED STUDY; DRUG POTENCY; ENHANCED THROUGHPUT AUTOMATED PLATFORM; FLUOROMETRIC IMAGING PLATE READER; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LABORATORY AUTOMATION; PROCESS OPTIMIZATION; QUALITY CONTROL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SHIFT TO THE LEFT; CYTOLOGY; DRUG POTENTIATION; DRUG SCREENING; HIGH THROUGHPUT SCREENING; METHODOLOGY; PHARMACEUTICS;

AUTOMATION, LABORATORY; CYTOLOGICAL TECHNIQUES; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ION CHANNELS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84863813096     PISSN: 22110682     EISSN: 22110690     Source Type: Journal    
DOI: 10.1177/2211068211435301     Document Type: Article

References (27)

1. Hall, D. A. Modeling the Functional Effects of Allosteric Modulators at Pharmacological Receptors: An Extension of the Two-State Model of Receptor Activation. Mol. Pharmacol. 2000, 58(6), 1412-1423.
2. Christopoulos, A. Allosteric Binding Sites on Cell-Surface Receptors: Novel Targets for Drug Discovery. Nat. Rev. Drug Discov. 2002, 1, 198-210.
3. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric Modulation of G-Protein Coupled Receptors. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 1-51.
4. Bridges, T. M.; Lindsley, C. W. G-Protein-Coupled Receptors: From Classical Modes of Modulation to Allosteric Mechanisms. ACS Chem. Biol. 2008, 3(9), 530-541.
5. Christopoulos, A.; Kenakin, T. G-Protein Coupled Receptor Allosterism and Complexing. Pharmacol. Rev. 2002, 54, 323-374.
6. Möhler, H.; Fritschy, J. M.; Rudolph, U. A New Benzodiazepine Pharmacology. J. Pharmacol. Exp. Ther. 2002, 300(1), 2-8.
7. Mirza, N. R.; Munro, G. The Role of GABA(A) Receptor Subtypes as Analgesic Targets. Drug News Perspect. 2010, 23(6), 351-360.
8. Marino, M. J.; Conn, P. J. Direct and Indirect Modulation of the N-methyl D-aspartate Receptor. Curr. Drug Targets CNS Neurol. Disord. 2003, 1(1), 1-16.
9. Capelli, A. M.; Castelletti, L.; Salvagno, C.; Oliosi, B.; Di Lenarda, E.; Virginio, C.; Lightfoot, A.; Kew, J. N.; Teague, S. Identification of Novel alpha7 nAChR Positive Allosteric Modulators with the use of Pharmacophore In Silico Screening Methods. Bioorg. Med. Chem. Lett. 2010, 20(15), 4561-4565.
10. Johnson, M. P.; Baez, M.; Jagdmann, G. E., Jr.; Britton, T. C.; Large, T. H.; Callagaro, D. O.; Tizzano, J. P.; Monn, J. A.; Schoepp, D. D. Discovery of Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor: Synthesis and Subtype Selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J. Med. Chem. 2003, 46(15), 3189-3192.
11. Valenti, O.; Marino, M. J.; Conn, P. J. Modulation of Excitatory Transmission onto Midbrain Dopaminergic Neurons of the Rat by Activation of Group III Metabotropic Glutamate Receptors. Ann. N. Y. Acad. Sci. 2003, 1003, 479-480.
12. Hemstapat, K.; de Paulis, T.; Chen, Y.; Brady, A. E.; Grover, V. K.; Alagille, D.; Tamagnan, G. D.; Conn, P. J. A Novel Class of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Interact with a Site Distinct from That of Negative Allosteric Modulators. Mol. Pharmacol. 2006, 70(2), 616-626.
13. Sheffler, D. J.; Conn, P. J. Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 1a Differentially Modulate Independent Signaling Pathways in Baby Hamster Kidney Cells. Neuropharmacology 2008, 55(4), 419-427.
14. Valant, C.; Aurelio, L.; Urmaliya, V. B.; White, P.; Scammells, P. J.; Sexton, P. M.; Christopoulos, A. Delineating the Mode of Action of Adenosine A1 Receptor Allosteric Modulators. Mol. Pharmacol. 2010, 78(3), 444-455.
15. 1 Muscarinic Acetylcholine Receptor Orthosteric and Allosteric Agonists. J. Pharmacol. Exp. Ther. 2008, 327, 365.
16. Yang, F. V.; Shipe, W. D.; Bunda, J. L.; Nolt, M. B.; Wisnoski, D. D.; Zhao, Z.; Barrow, J. C.; Ray, W. J.; Ma, L.; Wittmann, M.; et al. Parallel Synthesis of N-biaryl Quinolone Carboxylic Acids as Selective M(1) Positive Allosteric Modulators. Bioorg. Med. Chem. Lett. 2010, 20(2), 531-536.
17. Leach, K.; Loiacono, R. E.; Felder, C. C.; McKinzie, D. L.; Mogg, A.; Shaw, D. B.; Sexton, P. M.; Christopoulos, A. Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties. Neuropsychopharmacology 2010, 35(4), 855-869.
18. Gjoni, T.; Desreyaud, S.; Imobersteg, S.; Urwyler, S. The Positive Allosteric Modulator GS39783 Enhances GABA(B) Receptor-Mediated Inhibition of Cyclic AMP Formation in Rat Striatum In Vivo. J. Neurochem. 2006, 96(5), 1416-1422.
19. Pin, J. P.; Prézeau, L. Allosteric Modulators of GABA(B) Receptors: Mechanism of Action and Therapeutic Perspective. Curr. Neuropharmacol. 2007, 5(3), 195-201.
20. Ray, K.; Tisdale, J.; Dodd, R. H.; Dauban, P.; Ruat, M.; Northup, J. K. Calindol, a Positive Allosteric Modulator of the Human Ca(2+) Receptor, Activates an Extracellular Ligand-Binding Domain-Deleted Rhodopsin-Like Seven-Transmembrane Structure in the Absence of Ca(2+). J. Biol. Chem. 2005, 280(44), 37013-37020.
21. Harrington, P. E.; Fotsch, C. Calcium Sensing Receptor Activators: Calcimimetics. Curr. Med. Chem. 2007, 14(28), 3027-3034.
22. Jensen, A. A.; Bräuner-Osborne, H. Allosteric Modulation of the Calcium-Sensing Receptor. Curr. Neuropharmacol. 2007, 5(3), 180-186.
23. Kennedy, J. P.; Williams, L.; Bridges, T. M.; Daniels, R. N.; Weaver, D.; Lindsley, C. W. Application of Combinatorial Science on Modern Drug Discovery. J. Comb. Chem. 2008, 10, 345-354.
24. Schwartz, Y. W.; Holst, B. Allosteric Enhancers, Allosteric Agonists, and Ago-Allosteric Modulators: Where Do They Bind and How Do They Act? Trends Pharmacol. Sci. 2007, 28, 366-373.
25. O'Brien, J. A.; Lemaire, W.; Chen, T. B.; Chang, R. S.; Jacobson, M. A.; Ha, S. N.; Lindsley, C. W.; Schaffhauser, H. J.; Sur, C.; Pettibone, D. J.; et al. A Family of Highly Selective Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5. Mol. Pharmacol. 2003, 64, 731-740.
26. Sharma, S.; Rodriguez, A. L.; Conn, P. J.; Lindsley, C. W. Synthesis and SAR of a mGluR5 Allosteric Partial Antagonist Lead: Unexpected Modulation of Pharmacology with Slight Structural Modifications to a 5-(Phenylethynyl)pyrimidine Scaffold. Bioorg. Med. Chem. Lett. 2008, 18(14), 4098-4101.
27. Lindsley, C. W.; Wisnoski, D. D.; Leister, W. H.; O'Brien, J. A.; Lemaire, W.; Williams, D. L., Jr.; Burno, M.; Sur, C.; Kinney, G. G.; Pettibone, D. J.; et al. Discovery of Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 5 from a Series of N-(1,3-diphenyl-1H-pyrazol-5yl)benzamides That Potentiate Receptor Function In Vivo. J. Med. Chem. 2004, 47, 5825-5828.